by Wim Mees | May 25, 2022 | Article, News, Press release
CureVac (Nasdaq: CVAC) and myNEO Therapeutics will partner to identify novel targets for mRNA-based cancer vaccine development. We’re convinced that combining our tumor characterization and neoantigen discovery methods with an mRNA vaccination technology holds great...
by Wim Mees | May 3, 2022 | Article, News
Abera Bioscience, a listed Swedish company with vaccine platforms for prophylactic and therapeutic vaccines today signed an agreement with Belgian company myNEO Therapeutics for collaboration within the neoantigen discovery field. The companies will work closely...
by Wim Mees | Mar 15, 2022 | Article, News
Opgeven Is Geen Optie (OIGO) is organizing an info session on March 24th where Lien Lybaert will explain in understandable language to cancer patients, their loved ones & sympathizers what has fascinated her for 10 years now: IMMUNOTHERAPY. What is the role of the...
by Wim Mees | Nov 2, 2021 | Article, News
EIT Health Catapult provides investors and industry representatives an excellent opportunity to gain access to a concentrated elite group of top European start-up companies keen to collaborate with strong partners, when they take their first steps towards economic...
by Wim Mees | Oct 20, 2021 | Article, News
The biotech industry in Ghent is very much alive. This is also proven by myNEO Therapeutics a young company that develops neoantigen discovery technology for personalized cancer treatments. Through sequencing of the entire genome, a technique that has been around for...
by Wim Mees | Oct 6, 2021 | Article, News
myNEO Therapeutics has been nominated for the 2021 Rising Star award, together with 9 other innovative companies! The Rising Star selection is part of the Deloitte Technology Fast 50 competition and is designed for promising companies that have been active in the...